Amyloidogenicity and Aggregate Cytotoxicity of Human Glucagon-Like Peptide-1 (hGLP-1)

Author(s): S. Poon, N. R. Birkett, S. B. Fowler, B. F. Luisi, C. M. Dobson, J. Zurdo.

Journal Name: Protein & Peptide Letters

Volume 16 , Issue 12 , 2009

Become EABM
Become Reviewer

Abstract:

The potential of human glucagon-like peptide-1 (hGLP-1) as a therapeutic agent is limited by its high aggregation propensity. We show that hGLP-1 forms amyloid-like structures that are preceded by cytotoxic aggregates, suggesting that aggregation of biopharmaceuticals could present a cytotoxic risk to patients besides the reported increased risk in immunogenicity.

Keywords: hGLP-1, protein aggregation, biopharmaceuticals, diabetes, amyloid fibrils, Alzheimer's disease

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 16
ISSUE: 12
Year: 2009
Page: [1548 - 1556]
Pages: 9
DOI: 10.2174/092986609789839232
Price: $58

Article Metrics

PDF: 13